Suratadenoturev is under clinical development by Chugai Pharmaceutical and currently in Phase I for Oropharyngeal Cancer. According to GlobalData, Phase I drugs for Oropharyngeal Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Suratadenoturev’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Suratadenoturev overview

Suratadenoturev (OBP-301) is under development for the treatment of gastric cancer,  gastroesophageal junction adenocarcinoma, head and neck cancer squamous cell carcinoma, hepatocellular carcinoma, esophageal squamous cell cancer, esophageal adenocarcinoma, head and neck squamous cell cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, oral cavity (mouth) cancer, metastatic melanoma, non small cell lung cancer, neuroblastoma  and hepatocellular carcinoma. The drug candidate is administered by intratumoral route. It is a therapeutic modality derived from adenovirus. Telomelysin is generated by replacing the normal transcriptional regulatory element of the E1A gene in the human adenovirus type 5 with the human telomerase reverse transcriptase (hTERT) promoter (oncolytic type 5 adenovirus). The drug candidate is developed based on oncolytic adenovirus technology. It was also under development for the treatment of sarcoma. The drug candidate is an new molecular entity (NME).

Chugai Pharmaceutical overview

Chugai Pharmaceutical (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is focused on the research, development, manufacturing, commercialization, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

For a complete picture of Suratadenoturev’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.